Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label, Multicenter Phase I/II Study: Salvage Therapy of Progressive and Relapsed Aggressive Non-Hodgkin-Lymphoma by Combination of Lenalidomide (Revlimid®) With Rituximab, Dexamethason, High-dose ARA-C and Cisplatinum (R²-DHAP)

NCT02983097 is registered in ClinicalTrials.gov with Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH as lead sponsor.

NCT NCT02983097
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02983097 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label, Multicenter Phase I/II Study: Salvage Therapy of Progressive and Relapsed Aggressive Non-Hodgkin-Lymphoma by Combination of Lenalidomide (Revlimid®) With Rituximab, Dexamethason, High-dose ARA-C and Cisplatinum (R²-DHAP)
Lead sponsor
Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH
Phase
Phase 1/2
Overall status
Terminated
Start date
November 30, 2010
Completion date
April 28, 2015
Enrollment
34 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

aggressive marginal zone lymphoma (mzl), burkitt lymphoma (bl), diffuse large b-cell lymphoma (dlbcl), follicular lymphoma grade iii (fl iii°), mantle cell lymphoma (mcl), blastoid variant